Dachaigh › Luchd-obrach › Janssen Scientific Affairs, LLC
Janssen Scientific Affairs, LLC: Tuarastalan H-1B agus taic bhìosa
Chuir Janssen Scientific Affairs, LLC 17 iarrtasan cumha-obrach a-steach airson bhìosaichean H-1B agus bhìosaichean co-cheangailte ann am bliadhnaichean ionmhais 2023–2026; le teisteanas: 17. Tuarastal meadhanach a chaidh a thabhann: $190,000.
A bheil Janssen Scientific Affairs, LLC a’ toirt taic do bhìosaichean H-1B?
Chuir Janssen Scientific Affairs, LLC 17 iarrtasan cumha-obrach a-steach ann am bliadhnaichean ionmhais 2023–2026, an tè as ùire air a chur a-steach air 9 Ògmh 2026. Is e LCA a’ chiad cheum ann an iarrtas H-1B, mar sin tha an neach-fastaidh air taic a thoirt do luchd-obrach H-1B no air ullachadh airson sin a dhèanamh; cha gharantaich e taic airson dreuchd shònraichte sam bith. Thoir sùil air liostaichean obrach an neach-fastaidh fhèin.
Iarrtasan cairt uaine (PERM) aig Janssen Scientific Affairs, LLC: 4 →
Tuarastalan a rèir tiotal obrach
| Tiotal dreuchd | LCAs | Tuarastal meadhanach |
|---|---|---|
| Associate Director, Real World Value and Evidence - Oncology | 3 | $195,000 |
| Manager, Real World Value & Evidence, Oncology | 2 | $168,900 |
| Principal Scientific Account Lead | 2 | $163,500 |
| Associate Director, Content Strategy and Innovation | 1 | $209,200 |
| Director, Real World Value & Evidence, Oncology | 1 | $220,000 |
| Associate Director, Real World Value & Evidence, Oncology | 1 | $196,200 |
| Integrated Evidence Team Leader, Aticaprant | 1 | $233,400 |
| Senior Manager HEOR ( Healthcare Economics & Outcomes) | 1 | $173,310 |
| Manager, Search Solutions | 1 | $183,600 |
| Associate Director, RWVE Oncology | 1 | $182,800 |
| Senior Medical Science Liaison (MSL) | 1 | $200,000 |
| Associate Director, Real World Value and Evidence–Hematology | 1 | $185,000 |
| Director Real World Value and EOH | 1 | $255,200 |
Iarrtasan a rèir bliadhna ionmhais
| Bliadhna mhaoine | LCAs | Tuarastal meadhanach |
|---|---|---|
| FY2023 | 3 | $209,200 |
| FY2024 | 4 | $179,155 |
| FY2025 | 5 | $183,600 |
| FY2026 | 5 | $195,000 |
Ìrean tuarastail làithreach
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Far a bheil na h-obraichean
Dreuchdan
- Medical and Health Services Managers4
- Data Scientists3
- Natural Sciences Managers3
- Medical Scientists, Except Epidemiologists3
- Market Research Analysts and Marketing Specialists2
- Epidemiologists1
- Molecular and Cellular Biologists1
Iarrtasan as ùire
| Tiotal dreuchd | Tuarastal bunasach | Àite | Air a chur a-steach | Ceann-latha tòiseachaidh | Inbhe |
|---|---|---|---|---|---|
| Director Real World Value and EOH | $255,200 Ìre IV | Horsham, PA | 9 Ògmh 2026 | 18 Dàmh 2026 | Dearbhaichte |
| Associate Director, Real World Value and Evidence–Hematology | $185,000 Ìre IV | Horsham, PA | 14 Gibl 2026 | 20 Gibl 2026 | Dearbhaichte |
| Principal Scientific Account Lead | $137,000–$274,000 Ìre IV | Exton, PA | 31 Dùbh 2025 | 19 Màrt 2026 | Dearbhaichte |
| Associate Director, Real World Value and Evidence - Oncology | $195,000 Ìre III | Livingston, NJ | 5 Samh 2025 | 18 Samh 2025 | Dearbhaichte |
| Senior Medical Science Liaison (MSL) | $200,000 Ìre IV | Kenmore, WA | 3 Samh 2025 | 17 Samh 2025 | Dearbhaichte |
| Associate Director, RWVE Oncology | $182,800 Ìre IV | Horsham, PA | 2 Iuch 2025 | 30 Dùbh 2025 | Dearbhaichte |
| Manager, Search Solutions | $183,600 Ìre IV | Titusville, NJ | 11 Ògmh 2025 | 16 Ògmh 2025 | Dearbhaichte |
| Associate Director, Real World Value and Evidence - Oncology | $200,650 Ìre IV | Horsham, PA | 14 Cèit 2025 | 1 Dàmh 2025 | Dearbhaichte |
| Principal Scientific Account Lead | $190,000 Ìre IV | Titusville, NJ | 14 Cèit 2025 | 19 Sult 2025 | Dearbhaichte |
| Manager, Real World Value & Evidence, Oncology | $168,900 Ìre III | Horsham, PA | 19 Samh 2024 | 8 Faoi 2025 | Dearbhaichte |
| Associate Director, Real World Value and Evidence - Oncology | $185,000 Ìre IV | Horsham, PA | 23 Sult 2024 | 2 Dàmh 2024 | Dearbhaichte |
| Senior Manager HEOR ( Healthcare Economics & Outcomes) | $173,310 Ìre III | Titusville, NJ | 14 Cèit 2024 | 5 Samh 2024 | Dearbhaichte |
| Manager, Real World Value & Evidence, Oncology | $168,900 Ìre IV | Horsham, PA | 4 Gibl 2024 | 1 Dàmh 2024 | Dearbhaichte |
| Integrated Evidence Team Leader, Aticaprant | $233,400 E-3 · Ìre IV | Titusville, NJ | 28 Dùbh 2023 | 2 Gibl 2024 | Dearbhaichte |
| Associate Director, Content Strategy and Innovation | $209,200 Ìre IV | Titusville, NJ | 12 Ògmh 2023 | 1 Dàmh 2023 | Dearbhaichte |
| Director, Real World Value & Evidence, Oncology | $220,000 Ìre IV | Horsham, PA | 10 Cèit 2023 | 18 Dàmh 2023 | Dearbhaichte |
| Associate Director, Real World Value & Evidence, Oncology | $196,200 Ìre IV | Horsham, PA | 21 Gibl 2023 | 18 Dàmh 2023 | Dearbhaichte |
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).